Gland Pharma?s Singapore arm appoints Ajay Sahini as CEO

Gland Pharma announced that its subsidiary, Gland Pharma International Pte (Gland Singapore), has appointed Ajay Sahni as Chief Executive Officer (CEO), effective 2 November 2026.

Sahni will be responsible for overseeing the Cenexi business, a wholly owned step-down subsidiary of Gland Pharma. He will report to the CEO of Gland Pharma.

Ajay holds a bachelor?s degree in business administration from European University of Brussels, Belgium. Sahni has over 36 years of experience in FMCG & pharmaceutical industries. His expertise spans financial management, business development and general management.

Ajay in his previous leadership roles, was the managing director for Pinewood Healthcare, Ireland; managing director for Wockhardt Bio AG, Switzerland; president of Wockhardt France SAS and its subsidiaries.

He has a vast experience performing all kinds of roles including finance director, project manager- business development, director (financial control, planning and analysis), regional finance director for South and South-East Asia, president, and managing director in various companies viz., Sanofi SA, SanofiSynthelabo Inc., Sanofi-Synthelabo Pte., Ferring Pharmaceuticals, Wockhardt France SAS and multiple subsidiaries including Laboratoires Negma SAS, Wockhardt Bio AG. and Pinewood Healthcare.

Gland Pharma is a Hyderabad-based pharmaceutical company focused on generic injectables and ophthalmics. It operates in more than 60 countries under a business-to-business model and offers a broad portfolio of sterile injectable products, including vials, ampoules, pre-filled syringes, lyophilized vials, infusions, oncology and ophthalmic solutions.

The company?s consolidated net profit jumped 47.09% to Rs 316.96 crore in Q1 FY27 compared with Rs 215.48 crore in Q1 FY26. Revenue from operations climbed 19.57% YoY to Rs 1,800.27 crore in Q1 FY27.

The scrip 0.74% to settled at Rs 3097.50 on the BSE.

Powered by Capital Market - Live News